Delving into the Latest Updates on Axitinib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Axitinib (JAN/USAN), 阿西替尼, AG-013736

+ [13]

Target

VEGFR1 x VEGFR2 x VEGFR3

Action

antagonists

Mechanism

VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists)

Therapeutic Areas

NeoplasmsUrogenital DiseasesNervous System Diseases+ [7]

Active Indication

Metastatic Renal Cell CarcinomaUnresectable Renal Cell CarcinomaRenal Cell Carcinoma+ [17]

Inactive Indication

Acute Myeloid LeukemiaAdenocarcinoma, metastaticAdenoid Cystic Carcinoma+ [42]

Originator Organization

Pfizer Inc.

Active Organization

Akeso Biopharma Co., Ltd.

Bristol Myers Squibb Co.

Pfizer Inc.

+ [11]

Inactive Organization

AiViva BioPharma, Inc.

Merck Sharp & Dohme Corp.

License Organization

Strata Oncology, Inc.

Akeso Biopharma Co., Ltd.

Pfizer Inc.

Drug Highest PhaseApproved

First Approval Date

United States (27 Jan 2012),

Advanced Renal Cell Carcinoma

RegulationOrphan Drug (United States), Fast Track (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H18N4OS

InChIKeyRITAVMQDGBJQJZ-FMIVXFBMSA-N

CAS Registry319460-85-0

This phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy alone in treating patients with clear cell renal cell cancer that may have spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started to other places in the body (metastatic). Studies have shown that gut health (the gut microbiome) may impact the effectiveness of immunotherapy. The microbiome includes all of the bacteria and organisms naturally found in the digestive tract. MO-03, a type of biotherapy, contains material from living organisms that may help keep the digestive tract healthy and may help to increase the effect of immunotherapy. Immunotherapy with monoclonal antibodies, such as ipilimumab, nivolumab, pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are a type of angiogenesis inhibitor and tyrosine kinase inhibitor (TKI) that block certain proteins which may help keep tumor cells from growing and may also help prevent the growth of new blood vessels that tumors need to grow. Adding MO-03 to SOC immunotherapy may be more effective than SOC immunotherapy alone in treating patients with advanced or metastatic clear cell renal cell cancer.

Start Date10 Jun 2026

Sponsor / Collaborator

SWOG

[+1]

NCT07516132

/ Not yet recruitingPhase 3

A Phase 3b, Multicenter, Open-Label, Extension Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Start Date01 Apr 2026

Sponsor / Collaborator

Ocular Therapeutix, Inc.

[+1]

NCT07500831

/ Not yet recruitingNot ApplicableIIT

Fasting-Mimicking Diet Combined With Toripalimab Plus Axitinib for Metastatic or Unresectable Renal Cell Carcinoma: A Single-Arm, Open-Label, Single-Center Clinical Trial

This study is testing whether adding a 5-day fasting-mimicking diet (FMD) can help people with advanced kidney cancer when given together with standard first-line cancer medicines.

Start Date01 Apr 2026

Sponsor / Collaborator

Qilu Hospital of Shandong University

100 Clinical Results associated with Axitinib

Login to view more data

100 Translational Medicine associated with Axitinib

Login to view more data

100 Patents (Medical) associated with Axitinib

Login to view more data

2,564

Literatures (Medical) associated with Axitinib

01 Dec 2026·CURRENT TREATMENT OPTIONS IN ONCOLOGY

Systemic Therapy for Salivary Gland Cancers: A Review of Targeted and Chemotherapeutic Approaches

Review

Author: Chintakuntlawar, Ashish ; Hintze, Justin M

OPINION STATEMENT:

Systemic therapy for recurrent and metastatic salivary gland malignancies (SGMs) remains a major therapeutic challenge. Traditional chemotherapy offers modest response rates with limited durability, and its role is largely palliative. The most meaningful advances have occurred in biomarker-selected subgroups: androgen receptor blockade for AR-positive salivary duct carcinoma and HER2-directed therapy for HER2-positive tumors have demonstrated superior response rates and survival (often exceeding 50%), compared with the single digit response rates seen with unselected chemotherapy or tyrosine kinase inhibitors. Small-molecule tyrosine kinase inhibitors such as lenvatinib and axitinib may provide disease stabilization in adenoid cystic carcinoma, although tumor shrinkage is uncommon and toxicity limits their long-term use. Immunotherapy as a single agent has been disappointing, but durable responses in select patients and modest activity with combination regimens suggest it may have a future role when rationally paired with other agents. In our practice, comprehensive molecular profiling is essential at the time of recurrence to identify actionable alterations, prioritize targeted therapy where available, and guide clinical trial enrollment. For most patients without a targetable alteration, platinum-based combinations remain the pragmatic choice, though expectations for benefit should be tempered. Future strategies will likely hinge on optimizing biomarker-driven therapies, expanding access to antibody-drug conjugates, and pursuing collaborative trial designs to overcome the rarity and heterogeneity of these tumors.

01 Apr 2026·UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma

Article

Author: Zukov, Ruslan ; Abdrakhmanov, Ramil ; Kaidarova, Dilyara ; Baklanova, Olga ; Musaeva, Gunel ; Ongarbayev, Bakytzhan ; Tsimafeyeu, Ilya ; Petkau, Vladislav ; Chubenko, Vyacheslav ; Guliyev, Fuad

BACKGROUND:

Patterns of progression under immuno-oncology regimens in metastatic renal cell carcinoma (mRCC) remain poorly described. This study characterizes site-specific disease progression in patients receiving first-line dual immunotherapy or immunotargeted therapy.

METHODS:

This retrospective, observational cohort study included patients with clear-cell metastatic renal cell carcinoma treated between 2018 and 2024 with standard-dose regimens of nivolumab-ipilimumab (IO-IO) or pembrolizumab-axitinib and avelumab-axitinib combinations (IO-axitinib). The primary endpoint was the occurrence of new metastatic lesions at progression. Secondary endpoints included progression by >20% increase in target lesion size.

RESULTS:

Of 334 patients identified, 233 were evaluable for analysis. Radiographic progression occurred in 86.3% of IO-IO and 60% of IO-axitinib. Development of new metastatic lesions was more frequent with Nivo-Ipi (39.3% vs. 22.2%), most commonly involving the lungs and bones. In contrast, IO-axitinib combinations showed a greater propensity for progression through enlargement of pre-existing lesions (77.8% vs. 60.7%), accompanied by the emergence of new adrenal gland metastases. Across both treatment groups, lymph nodes emerged as the most frequent new site of disease progression.

CONCLUSIONS:

Nivo-Ipi was associated with more frequent development of new metastatic lesions, particularly in the lungs, bones, and lymph nodes, while axitinib-based combinations more often resulted in regrowth of existing disease with higher rates of adrenal involvement.

01 Mar 2026·MedComm

Tislelizumab Combined With Axitinib in Neoadjuvant Treatment of Locally Advanced Clear Cell Renal Cell Carcinoma: A Single‐Center, Phase II Clinical Study

Article

Author: Jiang, Bo ; Ji, Changwei ; Yang, Wenjin ; Zhang, Shun ; Zhang, Gutian ; Wang, Xin ; Liu, Guangxiang ; Guo, Hongqian ; Li, Hao

ABSTRACT:

Clear cell renal cell carcinoma (ccRCC) accounts for 70%‒80% of renal cell carcinoma cases and often shows no symptoms in early stages. Thus, approximately 30% of patients are diagnosed with advanced ccRCC. This single‐center prospective single‐arm study evaluated the efficacy and safety of tislelizumab combined with axitinib in patients with locally advanced ccRCC. A total of 20 eligible patients were enrolled at Nanjing Drum Tower Hospital from September 2021 to June 2024. The primary endpoint was objective response rate (ORR) before surgery, and secondary endpoints included disease‐free survival (DFS), overall survival, safety, and tissue biomarker analysis. All patients completed neoadjuvant treatment, and 19 underwent planned surgery; 70% (14/20) had cT3 stage disease with a median tumor diameter of 8.3 cm. The ORR was 55% (11 partial responses), 73.6% (14/19) achieved pathological downstaging, one patient attained pathological complete response, and no grade ≥3 perioperative complications occurred. The 2‐year DFS rate was approximately 90%, and biomarker analysis showed significantly higher tumor shrinkage rates in patients with RTK/RAS pathway alterations. In conclusion, tislelizumab combined with axitinib exhibits substantial efficacy and acceptable safety in neoadjuvant treatment of locally advanced ccRCC, providing preliminary clinical evidence for its application.

571

News (Medical) associated with Axitinib

28 Apr 2026

·www.biospace.com

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026. Conference Call and Webcast Information : Date: Tuesday, May 5, 2026 at 8:00 AM ET Participant Dial-In (U.S.): 1-800-343-4136 Participant Dial-In (International): 1-203-518-9843 Conference ID: OCULAR (required for entry) Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com

Phase 3Phase 2Financial StatementDrug Approval

27 Apr 2026

·www.biospace.com

Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences

BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in May 2026. Upcoming Investor Conferences : Bank of America Health Care Conference 2026 : Date: Tuesday, May 12, 2026 Fireside Chat: 3:40 – 4:10 PM PDT Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO Location: Las Vegas, NV Stifel 2026 Virtual Ophthalmology Forum : Date: Tuesday, May 26, 2026 Fireside Chat: 2:30 – 2:55 PM EDT Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO Location: Virtual A live webcast of the Bank of America and Stifel fireside chats can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation. Upcoming Scientific Conferences : Eyecelerator @ ARVO 2026: May 1, 2026 Denver, CO Presentation: Ocular Therapeutix: Retina Experience Redefined Presentation Date/Time: Friday, May 1, 2026, 2:18 – 2:23 PM MDT Presenter: Peter K. Kaiser, MD, Chief Development Officer at Ocular Therapeutix ARVO 2026 Annual Meeting : May 3 - 7, 2026 Denver, CO Presentation: Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Phase 3 SOL-1 Trial Results Presentation Date/Time: Tuesday, May 5, 2026, 1:15 – 1:30 PM MDT Presenter: Patricio G. Schlottmann, MD Poster Title: Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database Session Date/Time: Thursday, May 7, 2026, 8:00 – 9:45 AM MDT Presenter: Andrew A. Moshfeghi, MD, MBA, FASRS Poster Title: Anti-VEGF Treatment Patterns and Long-Term Vision Outcomes in Patients with nAMD in the IRIS Registry Session Date/Time: Thursday, May 7, 2026, 8:00 – 9:45 AM MDT Presenter: Christina Y. Weng, MD, MBA Retina World Congress (RWC) 2026 : May 14 - 17, 2026 Fort Lauderdale, FL Presentation Title: Ocular Therapeutix: Retina Experience Redefined Presentation Date/Time: Thursday, May 14, 2026, 8:15 – 8:20 AM EDT Presenter: Peter K. Kaiser, MD, Chief Development Officer at Ocular Therapeutix Presentation Title: Update on Latest TKI data from the OTX-TKI program Presentation Date/Time: Friday, May 15, 2026, 4:30 – 4:35 PM EDT Presenter: Dilsher S. Dhoot, MD Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control Symposium Date/Time: Friday, May 15, 2026, 7:15 – 8:15 PM EDT Presenters: Patricio G. Schlottmann, MD; Dilsher S. Dhoot, MD; Mark R. Barakat, MD The Royal College of Ophthalmologists Annual Congress 2026 : May 18 - 20, 2026 Manchester, UK Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control Symposium Date/Time: Tuesday, May 19, 2026, 12:30 – 1:30 PM BST Presenters: Adnan Tufail, MBBS, MD, FRCOphth; Darius M. Moshfeghi, MD; Dilsher S. Dhoot, MD Exact medical conference presentation times may be subject to change. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com

Phase 3Phase 2Drug Approval

22 Apr 2026

·www.biospace.com

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Ocular’s Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026 BEDFORD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced plans to host an Investor Day on Wednesday, June 17, 2026, in New York City. Click here to register for the live event, with virtual access available, which will begin at 2:00 PM ET. The Investor Day will include participation from Ocular Therapeutix senior leadership and prominent retinal disease key opinion leaders. Additional details will be provided in advance of the event. A live webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website. A replay of the webcast will be archived for at least 30 days following the presentation. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com

Phase 3Phase 2

100 Deals associated with Axitinib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03218	Axitinib	L01XE17	DB06626

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Metastatic Renal Cell Carcinoma	China	Pfizer Europe MA EEIG	22 Apr 2025
Unresectable Renal Cell Carcinoma	China	Pfizer Europe MA EEIG	22 Apr 2025
Renal Cell Carcinoma	Japan	Pfizer Japan, Inc.	29 Jun 2012
Advanced Renal Cell Carcinoma	United States	PF Prism CV	27 Jan 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glycogen Storage Disease Type II	Phase 3	United States	Ocular Therapeutix, Inc.	01 Apr 2026
Nonproliferative diabetic retinopathy	Phase 3	United States	Ocular Therapeutix, Inc.	17 Nov 2025
Wet age-related macular degeneration	Phase 3	United States	Ocular Therapeutix, Inc.	29 Jan 2024
Wet age-related macular degeneration	Phase 3	Argentina	Ocular Therapeutix, Inc.	29 Jan 2024
Locally Advanced Renal Cell Carcinoma	Phase 3	-	Merck Sharp & Dohme LLC	16 Sep 2016
Advanced cancer	Phase 3	Germany	Pfizer Inc.	01 Nov 2011
Advanced cancer	Phase 3	Italy	Pfizer Inc.	01 Nov 2011
Advanced cancer	Phase 3	Spain	Pfizer Inc.	01 Nov 2011
Advanced cancer	Phase 3	United Kingdom	Pfizer Inc.	01 Nov 2011
Neuroendocrine Tumors	Phase 3	Germany	Pfizer Inc.	01 Nov 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01744249 (AXINET trial (GETNE1107) \| AXINET, CTgov)	Phase 2/3	Neuroendocrine Tumors \| Advanced cancer \| Non Functioning Pancreatic Endocrine Tumor	256	Sandostatin LAR+Axitinib (Axitinib + Sandostatin LAR)	chxnsjtbpi(uixuwnfbzb) = cgxapklnen rxdohvpnqw (lwbnfgxiiw, xyvmpehepg - rlxgjxxekp) View more	-	28 Apr 2026
				Placebo+Sandostatin LAR (Placebo + Sandostatin LAR)	chxnsjtbpi(uixuwnfbzb) = whcieexbmv rxdohvpnqw (lwbnfgxiiw, cbrqtiezkx - tixksvtbud) View more
NCT01744249 (AXINET, Pubmed \| J Clin Oncol)	Phase 3	Advanced Pancreatic Neuroendocrine Tumor Ki-67 index	256	Axitinib + Axitinibde LAR	gqudpxvclj(pecaxgcmoy) = whasedaayi szkrridcia (fogqaqzheq ) View more	Negative	20 Mar 2026
				Placebo + Octreotide LAR	gqudpxvclj(pecaxgcmoy) = dhmfdixmxl szkrridcia (fogqaqzheq ) View more
NCT04698213 (Tide-A, ASCO_GU2026)	Phase 3	Metastatic Renal Cell Carcinoma	824	Intermittent Axitinib+Avelumab	kasjdzwson(zcnyzplrzq) = pwueilxcfn coyvmalevm (yiyowmkmoy )	Negative	26 Feb 2026
ASCO_GU2026	Not Applicable	Renal Cell Carcinoma First line	632	Pembrolizumab-axitinib (PA)	dzyujcbmqi(nhabyojdxl) = yqmjekexyv wdhbimggjk (znbufivfzk ) View more	Positive	26 Feb 2026
				Pembrolizumab-lenvatinib (PL)	dzyujcbmqi(nhabyojdxl) = wdaxwqhdfe wdhbimggjk (znbufivfzk ) View more
NCT06223958 (SOL-1, Company_Website) Manual	Phase 3	Wet age-related macular degeneration	344	AXPAXLI 0.45mg	ncsohnuvnh(sxjgjhqfhd) = zhjftxdkod qtovdbmhbb (qavxahchru ) Met View more	Superior	17 Feb 2026
				aflibercept (2 mg)	ncsohnuvnh(sxjgjhqfhd) = cibzciciml qtovdbmhbb (qavxahchru ) Met View more
ESMO_ASIA2025	Not Applicable	Metastatic Renal Cell Carcinoma First line	194	IO-IO (nivolumab + ipilimumab)	fdntmeweuv(zvckocsbsx) = wwzujxawpa oegctaooji (mjkzpgpwnh, 1.0 - 55.9) View more	Positive	05 Dec 2025
				IO-TKI (pembrolizumab + axitinib or lenvatinib or nivolumab + cabozantinib)	fdntmeweuv(zvckocsbsx) = mwtwucukvq oegctaooji (mjkzpgpwnh, 1.0 - 45.2) View more
ASN2025	Not Applicable	Advanced Renal Cell Carcinoma First line	886	Axitinib plus Avelumab	ggvujcgtvt(lmwwrrsmmp) = bpiunaejjo pvuzgscsmb (oyruslfipu ) View more	Positive	08 Nov 2025
				Sunitinib	zznyrkmptn(jtubzgdqlf) = bvdvyldqvr nevacopszh (jaclrmujxw )
NCT04370509 (CTgov)	Phase 2	Metastatic Renal Cell Carcinoma \| Advanced Renal Cell Carcinoma \| Renal Cell Carcinoma ... View more	6	Cytoreductive Nephrectomy (CN)+Pembrolizumab	aurhzyplel = wjxfdgjcyp xicvndovob (vfqqoyydwo, wqlobziksh - ryaomugraw) View more	-	05 Nov 2025
ESMO2025	Phase 2	Renal Cell Carcinoma	26	SintilimabAxitinibab + SintilimabAxitinib (Stereotactic Radiotherapy (SBRT))	iulwcbgtaa(jmphsiaztf) = ybkwyueuhu yepcritbok (dnjyzeowcv ) View more	Positive	17 Oct 2025
NCT03990571 (ESMO2025)	Phase 2	Adenoid Cystic Carcinoma NOTCH1 mutations \| MYC upregulation \| TP63 upregulation	22	Axitinib plus Avelumab	bujpdudcxg(mtqkiugirw) = hjfitwrwko wduflaqglw (hxfhyhxqff )	Positive	17 Oct 2025